July 17 (Reuters) - Danish drugmaker Novo Nordisk said on Friday that India's drug regulator has approved its obesity drug ...
The CDSCO has approved a new indication for Wegovy (semaglutide injection 2.4 mg) for treatment of noncirrhotic metabolic ...
Biopharma SHAKTI aims to build the research, clinical-trial and manufacturing ecosystem India needs to move from low-cost ...
Novo Nordisk's Wegovy receives CDSCO approval as India's first GLP-1 treatment for fatty liver disease, addressing rising ...
India is working on BioPharmaNext, a flagship mission aimed at making the country a global hub for the next generation of ...
The Supreme Court has registered a suo motu case to curb delays when it comes decisions on cases involving access to ...
A new NITI Aayog report proposes "BioPharmaNext" and a ₹50,000-crore growth fund to transition India's pharmaceutical sector ...
The Supreme Court took suo motu cognisance of a Kerala cancer drug case, questioning why the matter remained undecided ...
Police have attached properties worth about Rs 65 lakh belonging to two alleged drug peddlers in Jammu and Rajouri districts ...
India's drug regulator has approved Novo Nordisk's obesity drug Wegovy to treat MASH, a progressive fatty liver disease ...
Mangaluru CCB police arrested two men from Belthangady taluk on 15 July in Bagalkote district while they were transporting a ...
Health and Me on MSN
Novo Nordisk's GLP-1 drug Wegovy approved for fatty liver disease in India
Novo Nordisk said that Wegovy is the first and only GLP-1 receptor agonist (GLP-1 RA) approved globally and in India for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results